Thrombocytopenia is an autoimmune hematological bleeding disorder characterized by blood in urine, headaches, heavy menstrual period, spots on skin, and bruises. It can also be caused by cancer medications, including chemotherapy and drug-induced medicines, and radiation therapies.
Increasing prevalence rates for autoimmune hemolytic anemia is boosting the market growth.
Warm autoimmune hemolytic anemia (WAHA) is an autoimmune disorder characterized by the early destruction of healthy red blood cells (hemolysis).
It occurs when one's immune system attacks healthy tissue. In WAHA and other types of autoimmune hemolytic anemia, red blood cells are tagged by antibodies and destroyed by other types of immune cells. It is the most common type of autoimmune hemolytic anemia.
According to the National Organization for Rare Disorders, WAHA affects approximately 1 to 3 per 100,000 people every year and can occur at any age. Usually, the red blood cells have a life span of approximately 120 days before the spleen destroys them.
In patients with WAHA, the red blood cells are destroyed prematurely, and the increasing rate of new cells in the bone marrow can no longer pay for their loss. Additionally, the limited number of red blood cells may cause fatigue, weakness, a pale skin color (pallor), dizziness, palpitations, and shortness of breath (dyspnea).
The treatment of WAHA includes corticosteroids and rituximab. Therefore, individuals who do not react to the usual treatment might require drugs that suppress the immune system, blood transfusions, or surgical spleen removal (splenectomy).
North America region holds the largest market share in the global thrombocytopenia management market
North America dominated the market in 2020, owing to the rising thrombocytopenia cases, favorable government initiatives and high research funding in the region is expected to boost the market in the forecast period.
For instance, according to the Annals of Blood, published on March 2021, Immune thrombocytopenia (ITP) is a rare heterogeneous autoimmune bleeding disorder that makes a lower than normal circulating platelet count caused by impaired platelet production and accelerated platelet destruction.
Patients with ITP face a set of challenges. The multifaceted burden of living with ITP impacts patients and their families' overall health-related quality of life (HRQoL). Moreover, ITP leads to fatigue, challenges with daily activities, reduced physical functioning, anxiety, and depression. Aside from the constant risk for serious bleeding, patients experience physical and emotional consequences living with their disease daily.
Additionally, ITP is primarily chronic in adults, with a higher prevalence in women than in men. The prevalence of ITP is 20.3 per 100,000 persons in the United States of America (USA). Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Competitive Landscape
The thrombocytopenia management market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc., Amarillo Biosciences, Baxalta, Bayer, BioLineRx, Boehringer Ingelheim, Bolder Biotechnology, Bristol-Myers Squibb, Cellerant Therapeutics, Eisai, and Genosco.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the thrombocytopenia management market globally.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
